Subscribe To

Price Alert Latest News Economic Calendar News

RGLS / Regulus Therapeutics Announces Timing for Fourth Quarter and Year-End 2021 Financial Results Webcast and Conference Call

SAN DIEGO, March 3, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it has scheduled its fourth quarter and year-end 2021 financial results conference call and webcast on Thursday, March 10, 2022, after the U.S. financial markets close. In connection with the earnings release, Regulus' management team will host a live conference call and webcast at 5:00 PM ET on Thursday, March 10, 2022, to discuss the Company's financial results and provide a corporate update. Read More

Demo Live Account See Partner Details

Content Topics

Regulus

Therapeutics

Announces

Timing

Fourth

Quarter

Year end

Financial

Results

Webcast

Conference

Stock

RGLS

Posted: Mar 3 2022, 17:15

Author Name: PRNewsWire

RGLS News

By GuruFocus
August 23, 2023

Regulus Therapeutics Inc's Uncertain Future: Understanding the Barriers to Outperformance

Long-established in the Biotechnology industry, Regulus Therapeutics Inc ( RGLS , Financial) has enjoyed a stellar reputation. It has recently witness

By Zacks Investment Research
April 14, 2023

Regulus (RGLS) Surges on Enrollment Completion for RGLS8429

Regulus (RGLS) surges as it completes enrollment in the first cohort to evaluate RGLS8429 for kidney disease.

By Seeking Alpha
November 10, 2022

Regulus Therapeutics, Inc. (RGLS) Q3 2022 Earnings Call Transcript

Regulus Therapeutics, Inc. (NASDAQ:RGLS ) Q3 2022 Earnings Conference Call November 10, 2022 5:00 PM ET Company Participants Crispina Calsada - CFO Ja

By PRNewsWire
September 2, 2022

Regulus Therapeutics to Participate in Upcoming Investor Conferences

SAN DIEGO , Sept. 2, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and developme

By PennyStocks
May 23, 2022

Check These 3 Penny Stocks Out For Your Watchlist

Are these penny stocks on your watchlist right now? The post Check These 3 Penny Stocks Out For Your Watchlist appeared first on Penny Stocks to Buy

By InvestorPlace
May 17, 2022

7 Penny Stocks With 10x Potential This Year

These penny stocks all have 10x potential or greater during the remainder of 2022. They are risky but relatively straightforward.

By PennyStocks
May 15, 2022

How to Trade Penny Stocks When the Stock Market Crashes

Here are three tips for trading penny stocks during a bear market The post How to Trade Penny Stocks When the Stock Market Crashes appeared first on P

By Seeking Alpha
May 12, 2022

Regulus Therapeutics, Inc. (RGLS) CEO Joseph Hagan on Q1 2022 Results - Earnings Call Transcript

Regulus Therapeutics, Inc. (NASDAQ:RGLS ) Q1 2022 Earnings Conference Call May 12, 2022 5:00 PM ET Company Participants Crispina Calsada - CFO Joseph

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.